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A 52 year old female without comorbidity presented with AML. The karyotype was normal and 
molecular testing revealed mutations in FLT3 (ITD, allelic ratio 1.0), NPM1 and IDH2. She was 
enrolled into the NCRI AML19 study and received induction chemotherapy with daunorubicin, 
cytarabine and two doses of gemtuzumab. After second induction, NPM1 mutant transcripts were 
detected (Figure 1) in both the blood and bone marrow aspirate and the patient was allocated to 
intensification with CPX-351 (Vxyeos). On regeneration, transcript levels had increased by ~1 log and 
the patient was withdrawn from the trial protocol and received salvage therapy with the FLAG-Ida 
regimen. On regeneration, an MRD assessment showed a further ~2 log increase in transcript levels 
and the patient developed painless enlarged lymph nodes in the left side of the neck. A fine needle 
aspirate confirmed extramedullary disease. Quizartinib was initiated at a dose of 20mg daily and was 
increased to 60mg daily over a period of three weeks. A PET-CT scan confirmed that the 
extramedullary disease was confined to the left side of the neck and the patient received 5 fractions 
of radiotherapy to sites of extramedullary disease and was scheduled for allograft from a matched 
sibling. Pre-transplant MRD assessment showed a ~2 log reduction in disease-related transcripts and 
the patient proceeded to transplant. Conditioning was fludarabine (150mg/m2 IV) and busulphan 
(12.8mg/kg IV) and GvHD prophylaxis was cyclosporin and mycophenolate. MRD assessment at D+30 
was negative, weaning of immunosuppressive therapy was initiated and quizartinib was restarted. 
Further MRD assessments at D+60 and D+100 were negative. The patient developed chronic graft 
versus host disease affecting the skin and oral mucosa which was managed with extracorporeal 
photopheresis and topical steroids. 
 
Case 2: 
A 23 year-old male with severe obesity presented with AML. The karyotype was normal and 
molecular testing revealed a mutation in NPM1 only. He did not enter a clinical trial and received 
induction therapy with daunorubicin and cytarabine and after second induction the bone marrow 
remained positive for disease related transcripts and the peripheral blood was not assessed. He 
received consolidation treatment with two cycles of high-dose cytarabine. MRD assessments 
performed on regeneration and 3 and 6 months after therapy showed persistence of NPM1 mutant 
transcripts and at 9 months there was a >2 log rise in expression levels (Figure 2). This was confirmed 
on a second sample and molecular progression was diagnosed. Salvage therapy with FLAG-Ida was 
initiated and after the second cycle there had been a 2-3 log reduction in the level of MRD which 
remained positive. The patient proceeded with a haploidentical transplant with a parental donor, 
conditioning was fludarabine (160mg/m2) and busulphan (12.8mg/kg) and GvHD prophylaxis was 
cyclophosphamide (50mg/kg on D+3 and +5), tacrolimus and mycophenolate. By D+100 all 
immunosuppression had been stopped and an MRD assessment showed persistent NPM1 mutant 
transcripts. This was confirmed on a second sample and persistent molecular disease was diagnosed. 
Donor lymphocyte infusion at a dose of 105 cells / kg was administered. After four weeks, the level of 
NPM1 mutated transcripts had decreased by 1 log and after eight weeks the patient tested MRD 




With the improvement of therapeutic strategies in hematological malignancies, traditional 
morphological response definitions such as complete remission1 are increasingly insufficient as they 
take no account of persistent malignant cells that are below the resolution of conventional 
techniques. Accurate measurement of this minimal or measurable residual disease (MRD) is crucial 
for more accurate prediction of relapse risk which in turn can be used to inform treatment intensity. 
Most of the methods for MRD detection are broadly similar across the hematological malignancies 
(Table 1).  The role of MRD in acute lymphoblastic and chronic lymphocytic leukemia (ALL and CLL) 
and multiple myeloma (MM) has been summarized elsewhere2–6. The assessment of MRD in acute 
myeloid leukemia (AML) is in some ways more challenging due to molecular and phenotypic 
heterogeneity and MRD assessment is not yet completely standardized. This review focuses on the 
current status of MRD in AML and in particular the use of MRD for selecting patients for stem cell 
transplant, and for pre- and post-transplant interventions.  
 
Risk classification at diagnosis 
Detailed characterization of patients using a range of diagnostic techniques is essential for optimal 
treatment of acute myeloid leukemia (AML)7. Morphology remains the cornerstone of diagnosis and 
can distinguish different subtypes based on cellular and differentiation features8, most obviously the 
M3 FAB subtype, which allows initiation of urgent therapy including ATRA9. Flow cytometry (FCM) is 
mandatory to confirm the diagnosis of AML and can be used to assign subtype based on specific cell 
surface markers that are expressed in particular phases during differentiation of hematopoietic cells 
(i.e. cluster of differentiation or CD markers)8. Although there is no clear relationship between 
immunophenotype and outcome, multi-color flow cytometry (MFC) allows rapid determination of 
cell surface antigen expression status which is critical given the increasing availability of 
immunotherapies (e.g. gemtuzumab ozogamycin). MFC can also provide early clues to the underlying 
cytogenetic and molecular lesion, for example both APL and NPM1 mutated AML have characteristic 
immunophenotypes10,11. Cytogenetic analysis provides the most powerful prognostic information in 
AML and a full karyotype , complemented by fluorescence in-situ hybridization (FISH), is needed to 
identify recurrent chromosome abnormalities which are strongly predictive of outcome and inform 
the ELN guidelines for risk classification7. Molecular genetic analysis provides further essential 
prognostic information12, which is particularly informative in patients with a normal karyotype, for 
example in the patients described here. As well as risk group assignment, molecular analysis is 
increasingly important for selection of patients for targeted therapies including small molecule 
inhibitors of FLT3, IDH1 and IDH2, which are now becoming widely available. 
In most AML clinical studies, the majority of patients are classified as intermediate risk and despite 
detailed molecular analysis at diagnosis, outcome prediction remains imperfect. Therefore, 
particularly in this group, treatment emergent factors such as MRD may be particularly informative 
with respect to selection of appropriate consolidation therapy13.   
 
Measurable residual disease (MRD) assessment during treatment 
The majority of AML patients treated with induction chemotherapy achieve a morphological 
complete remission (i.e. <5% blasts by morphology1). However, this is not a very sensitive method to 
accurately determine the residual load of leukemia cells13,14. More sophisticated methods for 
detection of residual disease can provide sensitivity orders of magnitude higher than that achieved 
by morphology. MRD status during treatment effectively provides a read out of multiple patient and 
leukemia specific characteristics, not all of which are well understood. There are several methods to 
detect MRD in blood and bone marrow of AML patients during therapy which include MFC, 
amplification of leukemia specific transcripts by reverse-transcription quantitative PCR (RT-qPCR)15–20 
and more recently, detection of leukemia-specific mutations using next-generation sequencing21–23. 
Details of the applicability of the different methods are summarized in Table 1. 
MRD status has been robustly correlated with risk of relapse in many independent large clinical trials.   
The prognostic value has been shown as early as after the first cycle of treatment. Many studies use 
MRD status after the second cycle of treatment to further refine risk classification since this time 
point has significant prognostic value and still allows enough time to initiate logistics for stem cell 
transplantation (SCT) when necessary. 
Flow cytometric MRD can assess the efficacy of induction / consolidation or salvage on the dominant 
diagnostic  (or relapse) leukemic blast populations  by identifying  leukemia associated immune 
phenotypes (LAIPs) on at least 10-20% of leukemic blasts  in the diagnostic (or relapse) sample and 
monitoring these specific LAIPs during therapy24 .  Since the LAIP is based on aberrant expression of 
CD markers on the cell surface that are not present in healthy bone marrow, residual leukemia cells 
can also potentially be detected during therapy without knowledge of the diagnostic (or relapse) 
LAIPs. This is referred to as the “different from normal approach” (DfN) and can be applied when no 
diagnostic (or relapse) samples are available, for example when patients are referred to a transplant 
center without having previously been monitored there.  Additionally the DfN approach can detect 
any phenotypically aberrant leukemia subpopulations that may have been minor or undetectable at 
diagnosis but have expanded during therapy, potentially due to clonal evolution such as that 
observed following  transplants25,26.  Therefore the recommendation of the ELN is to combine both 
flow cytometric-MRD methods instead of limiting CD marker panels to the LAIPs found at diagnosis27.  
In the recently completed HOVON 132 trial, all markers were measured so when clinical data become 
available, potential relevance of novel upcoming clones can be established. The DfN approach 
however can lead to false positive results and therefore reduced specificity particularly when there is 
insufficient knowledge of progenitor phenotypes resulting from regeneration of the bone marrow 
after chemotherapy or transplant. Tracking the diagnostic or relapse LAIPs as biomarkers of the 
major pre-treatment leukemic populations may also be more appropriate when assessing the 
efficacy of novel treatment strategies to reduce the dominant leukemic clones.   At present however, 
flow cytometric MRD assays are not yet standardized and validated enough to be used as a surrogate 
endpoint.  Joint efforts of current MRD assessments implemented in the majority of clinical trials 
should facilitate this.  Several groups are currently collaborating to standardize (where needed) and 
harmonize (where possible) the flow cytometric MRD  methods28.   Additionally, several studies are 
currently directed towards computational approaches to objectify, simplify and speed up MRD 
assessments29.    
 
Molecular MRD analysis provides a highly sensitive alternative to MFC in patients with a validated 
target for RT-qPCR i.e. patients with recurrent in-frame gene fusions or NPM1 mutations (together 
accounting for ~60% of younger adults)30.  For patients with NPM1 mutated AML, molecular MRD 
analysis has demonstrated remarkable discrimination in a number of large prospective clinical trials 
and is the most powerful prognostic factor for these patients31–33, identifying those who will benefit 
from upfront transplantation. Apart from NPM1, prognostic impact of PML-RARA34, RUNX1-RUNX1T1 
and CBFB-MYH1115,19 fusion transcripts during treatment and follow-up is well established and the 
relevance of transcript status for other rarer fusion genes is currently being investigated in large 
prospective trials such as NCRI AML19 and MyeChild01.  Levels of expression of these leukemia-
specific transcripts at diagnosis varies markedly and this impacts on assay sensitivity35 for example, 
NPM1 mutant transcripts are highly expressed at diagnosis, resulting in sensitivity of up to 1:107 
whereas assays to monitor KMT2A fusions may only afford sensitivity orders of magnitude lower36. 
Molecular markers considered unsuitable on their own to monitor MRD include FLT3, due to its 
relative instability at relapse37.  
Assays for WT1 mutation and expression are generally no longer considered satisfactory for MRD 
measurement; while often upregulated or mutated at relapse, expression is insufficiently specific 
whereas mutation status is insufficiently sensitive to reliably detect relapse38.  
The most valuable addition to the current battery of assays35 would be the ability to measure all 
AML-associated mutations with the sensitivity required for MRD analysis using NGS. Therefore, many 
initiatives are currently ongoing to improve sensitivity and reproducibility of NGS-MRD, these will 
need to be completed before NGS can be uniformly introduced for MRD directed treatment 
allocation for clinical trials and in routine practice39. In addition to harmonization of the MRD assays,  
the combination of MFC and molecular analyses needs further evaluation, since it has recently been 
shown that these methods are complementary23. 
All current AML MRD platforms would benefit from further standardization and from unified criteria 
for MRD-positivity. Considering the progress in this40, it is anticipated that MRD might be accepted by 
the FDA as surrogate endpoint for treatment response in the near future.     
 
Besides improvements to the methods for MRD detection, uncertainties remain regarding thresholds 
for MRD positivity across AML subtypes,  treatment strategies and informative time-points as well as 
the utility of MRD by monitoring in peripheral blood samples.41–43 This is currently still under 
investigation and should become apparent within the next few years. 
 
Use of MRD to inform pre-transplant management 
Using a combination of comprehensive diagnostic profiling and MRD status, patients who are likely 
to be cured with chemotherapy alone and who can be safely monitored in CR1 can be discriminated 
from those who will benefit from upfront transplantation31,32.  Although there are currently no 
randomized data to support this approach, based on currently available non-randomized data this is 
approach has generally been adopted and is implemented in a number of large clinical trials (see for 
examples Table 2). Ongoing prospective studies will provide further information to guide decision 
making and in particular the UK NCRI “monitor versus no monitor” randomization will report next 
year and will be informative regarding the benefit of MRD-directed consolidation therapy. 
MRD positivity is thus a marker for selection of patients for allo-SCT. However, it has been shown 
that the risk of post-transplant relapse is lowest in MRD negative patients21,44–48 the question is 
therefore whether MRD-positive patients would benefit from intensification of treatment before SCT 
in order to convert to MRD negativity. Although superficially attractive, the potentially drug resistant 
MRD positive bone marrow may not easily become MRD negative, and this could lead to additional 
toxicity without benefit, which could potentially compromise long-term survival. There are currently 
no prospective data to inform such decisions, however ongoing studies such as UK NCRI COSI may be 
informative in this regard. In the absence of such data, individual patient management can be 
informed by sequential MRD measurement, and this is potentially an opportunity for use of novel 
relatively non-toxic targeted agents for the elimination of drug-resistant cell reservoirs prior to 
transplant. 
It also remains unclear whether augmented conditioning can improve the outcome for patients who 
are MRD positive before transplant; retrospective studies comparing myeloablative and reduced 
intensity conditioning for these patients have yielded conflicting results48,49. A retrospective study has 
suggested an advantage for MRD positive patients who receive umbilical cord blood transplants50 
although this remains controversial51 and importantly this approach removes the option of using 
donor lymphocyte infusion after transplant. Prospective studies to define the optimal management 
for these patients are urgently required. 
 
After stem cell transplantation 
For patients who remain persistently MRD positive after transplant, relapse is inevitable without 
further intervention. Treatment options depend on the clinical situation and time from transplant. 
Data to inform management of MRD positivity in the post-transplant setting are fairly sparse and 
indeed there is only 1 published prospective study to date. The RELAZA2 study demonstrated that 
azacitidine can prevent or delay hematological relapse in a proportion of patients with ongoing MRD 
positivity after treatment and this may be more effective in patients who have been transplanted, 
potentially indicating an immunological effect of this treatment52. Post-transplant MRD status may 
also be useful to plan withdrawal of immunosuppression; after this has been tapered persistent MRD 
positivity should prompt consideration of donor lymphocyte infusion (DLI).  A number of studies have 
reported very good success rates in this setting53,54. It appears that DLI can convert patients to MRD 
negativity and long-term disease-free survival rates of 80-100% have been reported in these small 
retrospective studies. Certainly, the success rates for the use of DLI in the MRD setting appear 
significantly higher than when DLI is used at hematological relapse55,56. Azacitidine in combination 
with DLI has also been reported to be effective in this situation56 and could be considered if DLI alone 
fails or the level of MRD is very high.  DLI is also reported to have activity in post-transplant MRD 
positivity in other hematological malignancies such as ALL57 and CML58. Based on these effective 
options for persistent or re-emergent MRD positivity, it is therefore recommended to perform serial 
MRD monitoring after transplant59 particularly for patients with a sensitive molecular marker where 
impending relapse can be predicted months in advance, providing a time window for intervention36. 
We suggest that post-transplant surveillance is continued for at least 1-2 years after transplant as 
this period is associated with the highest risk of relapse. A proportion of patients will be unable to 
receive DLI due either to the donor status or the presence of graft-versus-host disease (GVHD) and 
some of these patients will either not respond to, or be unable to tolerate azacitidine. For these 
patients, management is more challenging. In the absence of evidence, novel agents could be 
considered for example, FLT3 or BCL2 inhibitors. Further prospective clinical trials that utilize MRD 
directed post-transplant interventions are now required. Some studies that are in progress should 
give further insights in the near future; in this respect HOVON recently initiated a prospective phase 
III trial to determine the efficacy of panobinostat maintenance therapy versus standard of care after 
allo-SCT, which includes MRD assessment before and at several time points after SCT. 
 
Case discussions 
Case 1. This patient was ELN intermediate risk based on molecular and cytogenetic features at 
diagnosis however failure to achieve MRD negativity in the peripheral blood after second induction is 
associated with a very high risk of relapse20. For patients with FLT3 ITD, pre-transplant MRD positivity 
is associated with a high risk of post transplant relapse (Dillon EHA abstract 2019) therefore 
intensification was attempted but was unsuccessful and resulted in molecular and extramedullary 
progression indicating chemorefractory disease. In this situation, novel targeted agents may be 
useful to reduce disease burden prior to, and to sustain remission after transplantation, as illustrated 
by the effect of quizartinib in this case. 
 
Case 2. This patient was ELN favorable risk based on presentation at presentation, however at the 
end of treatment he remained persistently MRD positive indicating impending relapse. Due to a high 
risk of treatment related mortality, intervention was only undertaken after a significant rise in MRD 
levels. Although molecular complete remission was not regained after salvage therapy, patients who 
are FLT3 ITD negative with low levels of NPM1 mutant transcripts have a generally good outcome 
after transplant (Dillon EHA abstract 2019). Despite this, he remained MRD positive after withdrawal 
of immunosuppression. Donor lymphocyte infusion resulted in a rapid clearance of residual disease 
providing an example of the graft-versus-leukemia effect for eliminating MRD after transplant. 
 
Future perspectives 
Risk classification based on diagnostic cytogenetic and molecular characterization and refined by 
MRD assessment at early time points is critical for proper clinical decision making in AML. MRD 
provides the most powerful predictor of outcome in intermediate risk AML and its measurement 
both in clinical trials and everyday practice is strongly recommened60. MRD data can be exploited to 
tailor treatment intensity according to response and as shown here can serve as a trigger for 
application of novel therapies (such as FLT3 inhibitors, IDH1/2 inhibitors, splicing modulators or 
epigenetic modifiers)40,61.  
Although current MRD platforms provide very powerful prognostic information, further 
improvement is possible through standardization of assays and accumulation of larger data sets. 
These collaborative efforts will lead to a clearer definition of the optimum time points, sample 
sources and thresholds for clinical decision making. With regard to MFC MRD, a deeper 
understanding of the characteristics of relapse initiating cells may further improve prognostic value 
62,63. A recently designed one tube assay to assess leukemia stem cell (LSC) load is used in HOVON 
studies, which takes clonal evolution into account and which is associated with clinical outcome both 
at diagnosis and during therapy64.  In addition, it has been shown that combining molecular and MFC 
data also aids in distinguishing a very poor risk group who may benefit from intensified treatment 
strategies63.  
It is currently being investigated whether MRD can be used as surrogate endpoint in clinical trials to 
assess effectivity of treatment. This might considerably improve the development of new treatment 
options for the patient subgroups most likely to benefit from the intervention65. 
Finally, although few studies have yet been published regarding the use of MRD results to optimize 
peri-transplant management, this now appears to be an extremely promising field of study with the 
potential to test MRD-triggered interventions which could have a major impact on rate of post-
transplant relapse by focusing interventions on those patients at highest risk. Results of these 
emerging studies are eagerly anticipated. 
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Legends to figures 
Figure 1. Examples of molecular MRD monitoring of NPM1 mutations before and after therapy.  
A) Example of MRD guided pre-transplant management. See text for full case history. DA: 
daunorubicin and cytarabine. GO: gemtuzumab ozogamycin. FLAG-Ida: fludarabine, 
cytarabine, granulocyte colony stimulating factor and idarubicin. DXT: radiotherapy. FB4 Sib 
Allo: fludarabine and busulphan conditioned sibling allograft. 
 
B) Example of MRD guided therapy and peri-transplant management. See text for full case 
history. DA: daunorubicin and cytarabine. HDAC: high dose cytarabine. FLAG-Ida: fludarabine, 
cytarabine, granulocyte colony stimulating factor and idarubicin. FBC Haplo: fludarabine and 
busulphan conditioned haplo-identical allograft with and post-transplant cyclophosphamide. 
DLI: donor lymphocyte infusion. 
 
  
Table 1. Characteristics of the different currently used MRD methods 
  







































10-3 - 10-6 Does not require 
construction of patient-
specific  reagents,  
May detect clone shifts 
Expensive 68 
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10-4 - 10-5 Standardized primers Applicable in a 
limited number of 
patients 
34,35,58,69 
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DNA AML 10-3 - 10-5 Applicable in many         
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Insensitive without  
Error correction 
39 
Over expression   RT-Q-PCR WT1 RNA AML 10-5 Sensitive Applicable in a 
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Table 2: Clinical validation of MRD before and after transplant 
Study Patients 
(N) 
Patient group MRD method Time point Threshold Outcome Ref. 




Pre-transplant 0.1 % for FCM Prognostic for relapse and 
survival 
77 
EORTC/GIMEMA 81 MRD+ 
Eligible for SCT 
MFC After consolidation 0.035% No contra-indication for 
allo-SCT in MRD+ patients 
78 
IRCCS Genoa 224 Transplanted 
in CR1/CR2 
MFC and  
WT1 
Pre-transplant 2.5 x10-4 
250 copies/Abl × 104 
Prognostic value of MRD 
for pre- and post-
transplant interventions 
71 




Pre- and post- 
transplant (day 21) 
VAF0.2%-post-HCTD21 Good prediction of relapse 79 
Seattle 279 Adult MFC Pre- and post- 
transplant 




Hannover 116 > 18 years NGS In CR before transplant Error corrected  Predictive for relapse and 
survival 
Refine SCT  
21 
RELAZA2 60 MRD+ 







Depending on test 
used 
Predictive for relapse 52 
  
Figure 1. 
A) 
 
 
 
 
 
 
 
 
 
 
B) 
 
 
